JG
SMMT icon

Joel Greenblatt’s Summit Therapeutics SMMT Stock Holding History

Joel Greenblatt’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Hold
15,727
– – ﹤0.01% 1709
2026
Q1 		$298K Hold
15,727
– – ﹤0.01% 1607
2025
Q4 		$275K Hold
15,727
– – ﹤0.01% 1587
2025
Q3 		$325K Sell
15,727
-2
-0% -$49 ﹤0.01% 1495
2025
Q2 		$335K Sell
15,729
-56
-0.4% -$1.28K ﹤0.01% 1429
2025
Q1 		$304K Hold
15,785
– – ﹤0.01% 1356
2024
Q4 		$282K Sell
15,785
-123
-0.8% -$2.38K ﹤0.01% 1289
2024
Q3 		$348K Sell
15,908
-3,592
-18% -$50.2K ﹤0.01% 1191
2024
Q2 		$152K Buy
+19,500
New +$105K ﹤0.01% 1360

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Joel Greenblatt's SMMT Position: Q2 2026 in Review

Joel Greenblatt held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 15,727 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Joel Greenblatt first reported a position in SMMT in Q2 2024 and has held it in 9 quarters since. The position peaked at $348K in Q3 2024. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Joel Greenblatt held 15,727 shares of Summit Therapeutics worth $229K as of Q2 2026.
  • Joel Greenblatt left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1709 holding.
  • Joel Greenblatt first reported a position in Summit Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Joel Greenblatt's Summit Therapeutics position peaked at $348K in Q3 2024.
  • 241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.